← Back to Search

DNA Plasmid Therapy

30 mg dose of JVS-100 for Heart Failure (STOP-HF Trial)

Phase 2
Waitlist Available
Research Sponsored by Juventas Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

STOP-HF Trial Summary

This is a randomized, double-blind, placebo controlled Phase II study is designed to assess the safety and efficacy of using JVS-100 to treat heart failure.

Eligible Conditions
  • Heart Failure

STOP-HF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Impact of JVS-100 injection on Quality of Life at 4 month follow-up
Impact of JVS-100 injection on Six Minute Walk Distance (6MWD) at 4 month follow-up
Secondary outcome measures
Impact of JVS-100 Injection on LVEF
Impact of JVS-100 Injection on Major Adverse Cardiac Events
Impact of JVS-100 Injection on NYHA class
+4 more

STOP-HF Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: 30 mg dose of JVS-100Experimental Treatment1 Intervention
30 mg dose of JVS-100
Group II: 15 mg dose of JVS-100Experimental Treatment1 Intervention
15 mg dose of JVS-100
Group III: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Juventas Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
422 Total Patients Enrolled
3 Trials studying Heart Failure
254 Patients Enrolled for Heart Failure

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.
2012. "Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01643590.
All > Anterior Ischemic Optic Neuropathy
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top